Reta peptide guide
Reta peptide: mechanism, trial data, and research context
Published · Reviewed
Reta is shorthand for retatrutide (LY-3437943), an investigational single-molecule agonist of GLP-1, GIP and glucagon receptors. This guide separates established compound identity and trial findings from batch-level COA evidence; it does not provide clinical or personal-use guidance.
For in-vitro laboratory research only. Not for human or veterinary use.
What is reta peptide?
Reta peptide refers to retatrutide, also identified as LY-3437943. It is a peptide designed to activate three receptor pathways in one molecule: GLP-1, GIP and glucagon. Retatrutide remained investigational at this page's 30 July 2026 review; “reta” is an informal shorthand, while retatrutide is the compound name used in trials and publications. Lilly said it planned a US biologics license application in the first quarter of 2027.
How does reta work?
Retatrutide is designed as a triple agonist. GLP-1 and GIP are incretin pathways; glucagon-receptor activity is the additional mechanistic feature studied in relation to energy expenditure and liver-fat outcomes. Mechanism alone does not establish a clinical outcome.
For the deeper evidence trail, continue to the Remy Peptides retatrutide research profile and its receptor-by-receptor GLP-1, GIP and glucagon mechanism reference.
| Pathway | Research role | Why it matters |
|---|---|---|
| GLP-1 | Appetite and glycemic signaling | Shared with the broader GLP-1 class |
| GIP | Incretin amplification | Also present in tirzepatide-style dual agonism |
| Glucagon | Energy expenditure and liver-fat signaling | The added pathway that makes reta a triagonist |
What does reta do in research studies?
In research studies, reta is evaluated across body-weight change, glycemic markers, tolerability, liver-fat markers and energy expenditure pathways. Those findings are study observations, not a treatment recommendation. The safety profile is still being built through ongoing late-stage research.
Reta and weight loss trial data
The headline research reason people search for reta is weight-loss data. Lilly's Phase 2 announcement reported up to 17.5% mean weight reduction at 24 weeks and up to 24.2% at 48 weeks. The TRIUMPH-4 Phase 3 topline announcement reported 28.7% mean weight reduction at 68 weeks in the studied 12 mg arm. Those are study readouts, not guarantees or treatment claims.
TRANSCEND-T2D-1 is the clearest Phase 3 publication boundary at this review because its full randomized trial report was published in The Lancet. The 40-week study in adults with type 2 diabetes reported mean body-weight changes of −11.5%, −13.9% and −15.3% in the 4 mg, 9 mg and 12 mg groups, compared with −2.6% for placebo. The Phase 3 evidence tracker separates that peer-reviewed report from sponsor topline announcements.
On 23 July 2026, Lilly also reported sponsor topline results from two 80-week Phase 3 trials. TRIUMPH-2, in adults with obesity or overweight and type 2 diabetes, reported up to 20.8% mean body-weight reduction and up to a 1.6% A1C reduction in the 12 mg study arm under the efficacy estimand. TRIUMPH-3, in adults with severe obesity and established cardiovascular disease with or without type 2 diabetes, reported up to 22.6% mean body-weight reduction in the 12 mg study arm under the efficacy estimand. Detailed peer-reviewed reports were pending at this review.
Reta, energy expenditure, and glucagon signaling
The energy query attaches to reta because glucagon receptor activity is studied for energy expenditure. This is the main mechanistic distinction from GLP-1-only and GLP-1 / GIP dual-agonist pathways. The practical point for readers: reta is not just an appetite-pathway story; the research interest also sits in metabolic-rate and liver-fat signaling.
Reta and sleep apnea research
Sleep apnea is an adjacent search topic because body-weight change can affect obstructive sleep apnea severity in some study populations. That does not make reta a sleep apnea treatment claim. Reta-specific sleep apnea conclusions need dedicated trial outcomes, and this page treats the topic as research context only.
Reta vs tirzepatide
The simplest comparison is receptor design. Tirzepatide activates GLP-1 and GIP receptors. Reta activates GLP-1, GIP and glucagon receptors. For a deeper side-by-side view of dose architecture, half-life, weight-loss readouts and tolerability context, read the Reta vs Tirzepatide comparison.
Reta COA evidence
Mechanism pages answer what reta is. COA pages answer whether a research batch matches the label claim. The Remy Research COA library keeps Janoshik task IDs, HPLC purity, assay notes and verification keys together so a reader can move from article context to batch evidence without mixing the two. The 30mg pen format maps to batch RETP002, whose full analytical panel is published on this domain.
For documented 300-click 10mg, 20mg, and 30mg pen formats, the reta pen clicks-to-mg research calculator provides format-specific listed-material math. It is a laboratory-planning reference, not administration or personal-use guidance.
Research-use boundaries
Reta is presented here as an investigational research compound. Remy Research does not frame this article as medical advice, dosing instruction, a treatment claim, or a substitute for clinical evidence. Batch documentation is handled separately in the COA library.
Continue the evidence trail
For a source-state view of the late-stage program, open the Phase 3 evidence tracker. For batch-level analytical evidence, compare the published records in the COA library. For the separate US regulatory boundary, read the 2026 GLP-1 compounding landscape.
Sources
- Lilly Phase 2 NEJM announcement
- Lilly TRIUMPH-4 Phase 3 topline announcement
- NEJM Phase 2 obesity trial
- Lilly TRIUMPH-1 Phase 3 topline announcement
- Lilly TRIUMPH-2 and TRIUMPH-3 Phase 3 topline announcement (23 July 2026)
- TRANSCEND-T2D-1 Phase 3 publication in The Lancet
- TRANSCEND-T2D-1 trial record, NCT06354660
Common questions
What is reta (retatrutide)?
What is reta peptide (retatrutide)?
What does reta do?
How does reta (retatrutide) work?
What changed in the July 2026 Phase 3 update?
From the mechanism to the batch evidence
Once the pharmacology makes sense, the next question is purity. Open the COA library to check each Reta batch against its Janoshik report, task number and verification key.